印度血友病患者基因治疗知识和认知的调查

IF 0.6 4区 医学 Q4 HEMATOLOGY
Shruti Kharat, Shreyas Tawde, Cecil Ross, M Joseph John, Shruti Dabhade, Shrinath Kshirsagar, Kranti Patil, Gurpreet Kaur Saini, Apurva More, Nazish Kaunchale, Diksha Sarwan, Mridul Makkar, Magdalene D'silva, Shrushti Masurkar, Savita Rangarajan, Kalpana Hajirnis, Shrimati Shetty
{"title":"印度血友病患者基因治疗知识和认知的调查","authors":"Shruti Kharat, Shreyas Tawde, Cecil Ross, M Joseph John, Shruti Dabhade, Shrinath Kshirsagar, Kranti Patil, Gurpreet Kaur Saini, Apurva More, Nazish Kaunchale, Diksha Sarwan, Mridul Makkar, Magdalene D'silva, Shrushti Masurkar, Savita Rangarajan, Kalpana Hajirnis, Shrimati Shetty","doi":"10.1007/s12288-024-01945-1","DOIUrl":null,"url":null,"abstract":"<p><p>Novel molecules including gene therapy are used to treat haemophilia. Little is known on patient perceptions about gene therapy. Present survey is to assess the knowledge and identify key educational gaps and concerns about gene therapy in Indian persons with haemophilia (PWH). An explorative, qualitative, closed questionnaire based survey was conducted recruiting adult PWH from 3 Centers in India. Data were collected through face-to-face surveys or the patients themselves filling the survey forms. Of the 415 complete questionnaires received from adult severe PWH, approximately half of the PWH felt that gene therapy is the best option for PWH, but only 31.2% showed their willingness to be a part of any gene therapy clinical trial, if available. About 57% of the PWH were unable to decide about participation in clinical trials and 11.7% of the participants would never consider receiving gene therapy. Major concerns were cost, side effects, duration of expression and rejection, infection and risk of liver cancer. The PWH expressed their desire for information on subjects like eligibility criteria, earlier trial data, and details on safety. The survey shows a low level of knowledge about gene therapy in PWH and identifies gaps in knowledge and a strong willingness to understand more on the potential risk: benefit profile of gene therapy.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s12288-024-01945-1.</p>","PeriodicalId":49188,"journal":{"name":"Indian Journal of Hematology and Blood Transfusion","volume":"41 4","pages":"873-877"},"PeriodicalIF":0.6000,"publicationDate":"2025-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12515159/pdf/","citationCount":"0","resultStr":"{\"title\":\"A Survey to Assess the Knowledge and Perceptions about Gene Therapy in Indian Haemophilia Patients.\",\"authors\":\"Shruti Kharat, Shreyas Tawde, Cecil Ross, M Joseph John, Shruti Dabhade, Shrinath Kshirsagar, Kranti Patil, Gurpreet Kaur Saini, Apurva More, Nazish Kaunchale, Diksha Sarwan, Mridul Makkar, Magdalene D'silva, Shrushti Masurkar, Savita Rangarajan, Kalpana Hajirnis, Shrimati Shetty\",\"doi\":\"10.1007/s12288-024-01945-1\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Novel molecules including gene therapy are used to treat haemophilia. Little is known on patient perceptions about gene therapy. Present survey is to assess the knowledge and identify key educational gaps and concerns about gene therapy in Indian persons with haemophilia (PWH). An explorative, qualitative, closed questionnaire based survey was conducted recruiting adult PWH from 3 Centers in India. Data were collected through face-to-face surveys or the patients themselves filling the survey forms. Of the 415 complete questionnaires received from adult severe PWH, approximately half of the PWH felt that gene therapy is the best option for PWH, but only 31.2% showed their willingness to be a part of any gene therapy clinical trial, if available. About 57% of the PWH were unable to decide about participation in clinical trials and 11.7% of the participants would never consider receiving gene therapy. Major concerns were cost, side effects, duration of expression and rejection, infection and risk of liver cancer. The PWH expressed their desire for information on subjects like eligibility criteria, earlier trial data, and details on safety. The survey shows a low level of knowledge about gene therapy in PWH and identifies gaps in knowledge and a strong willingness to understand more on the potential risk: benefit profile of gene therapy.</p><p><strong>Supplementary information: </strong>The online version contains supplementary material available at 10.1007/s12288-024-01945-1.</p>\",\"PeriodicalId\":49188,\"journal\":{\"name\":\"Indian Journal of Hematology and Blood Transfusion\",\"volume\":\"41 4\",\"pages\":\"873-877\"},\"PeriodicalIF\":0.6000,\"publicationDate\":\"2025-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12515159/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Indian Journal of Hematology and Blood Transfusion\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1007/s12288-024-01945-1\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2025/1/13 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q4\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Indian Journal of Hematology and Blood Transfusion","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s12288-024-01945-1","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/1/13 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"HEMATOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

包括基因疗法在内的新分子被用于治疗血友病。患者对基因治疗的看法知之甚少。本调查旨在评估印度血友病患者(PWH)基因治疗方面的知识,并确定关键的教育差距和关注。一项探索性的、定性的、封闭式的问卷调查从印度的三个中心招募成年PWH。通过面对面调查或患者自行填写问卷的方式收集数据。在收到的415份来自成人重度PWH的完整问卷中,大约一半的PWH认为基因治疗是PWH的最佳选择,但只有31.2%的PWH表示他们愿意参加任何基因治疗临床试验,如果可能的话。大约57%的PWH无法决定是否参加临床试验,11.7%的参与者永远不会考虑接受基因治疗。主要关注的是成本、副作用、表达和排斥持续时间、感染和肝癌风险。PWH表示,他们希望获得有关资格标准、早期试验数据和安全性细节等主题的信息。调查显示,PWH对基因治疗的了解程度较低,并发现了知识上的差距,并且强烈希望了解更多基因治疗的潜在风险和益处。补充资料:在线版本包含补充资料,网址为10.1007/s12288-024-01945-1。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
A Survey to Assess the Knowledge and Perceptions about Gene Therapy in Indian Haemophilia Patients.

Novel molecules including gene therapy are used to treat haemophilia. Little is known on patient perceptions about gene therapy. Present survey is to assess the knowledge and identify key educational gaps and concerns about gene therapy in Indian persons with haemophilia (PWH). An explorative, qualitative, closed questionnaire based survey was conducted recruiting adult PWH from 3 Centers in India. Data were collected through face-to-face surveys or the patients themselves filling the survey forms. Of the 415 complete questionnaires received from adult severe PWH, approximately half of the PWH felt that gene therapy is the best option for PWH, but only 31.2% showed their willingness to be a part of any gene therapy clinical trial, if available. About 57% of the PWH were unable to decide about participation in clinical trials and 11.7% of the participants would never consider receiving gene therapy. Major concerns were cost, side effects, duration of expression and rejection, infection and risk of liver cancer. The PWH expressed their desire for information on subjects like eligibility criteria, earlier trial data, and details on safety. The survey shows a low level of knowledge about gene therapy in PWH and identifies gaps in knowledge and a strong willingness to understand more on the potential risk: benefit profile of gene therapy.

Supplementary information: The online version contains supplementary material available at 10.1007/s12288-024-01945-1.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
CiteScore
1.70
自引率
0.00%
发文量
82
审稿时长
>12 weeks
期刊介绍: Indian Journal of Hematology and Blood Transfusion is a medium for propagating and exchanging ideas within the medical community. It publishes peer-reviewed articles on a variety of aspects of clinical hematology, laboratory hematology and hemato-oncology. The journal exists to encourage scientific investigation in the study of blood in health and in disease; to promote and foster the exchange and diffusion of knowledge relating to blood and blood-forming tissues; and to provide a forum for discussion of hematological subjects on a national scale. The Journal is the official publication of The Indian Society of Hematology & Blood Transfusion.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信